Skip to main content

Table 2 Hazard ratio of 1% increase in GA and HbA1c levels for each endpoint

From: Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

 GAHbA1c
Cause of death Hazard ratio (95% CI)p valueHazard ratio (95% CI)p value
All-causesModel 11.00 (0.97–1.03)0.8150.87 (0.74–1.02)0.088
Model 21.01 (0.98–1.05)0.5170.92 (0.77–1.11)0.392
Model 31.03 (1.01–1.06)0.0171.01 (0.87–1.17)0.888
Model 11.08 (1.01–1.15)0.0161.12 (0.80–1.58)0.518
ASCVDModel 21.09 (1.02–1.17)0.0131.14 (0.78–1.66)0.501
Model 31.10 (1.05–1.16)< 0.0011.35 (1.02–1.77)0.033
Model 10.99 (0.95–1.02)0.4770.82 (0.68–0.99)0.034
Non-ASCVDModel 20.99 (0.96–1.03)0.6860.88 (0.71–1.08)0.206
Model 31.01 (0.98–1.05)0.4090.93 (0.78–1.10)0.374
  1. Model 1, in which the hazard ratios were estimated using baseline GA or HbA1c values; model 2, which used mean values of GA or HbA1c during the follow-up period; and model 3, in which GA or HbA1c values during the follow-up period were treated as time-dependent variables
  2. ASCVD atherosclerotic cardiovascular disease, GA glycated albumin, HbA1c hemoglobin A1c